Work

IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e21134

Authors: Gary Edward Richardson, John J. Park, Michael J. Boyer, Martin Gutierrez, David Paul Carbone, Panayiotis Savvides, Pravin Kaumaya, Tanios S. Bekaii-Saab, Tri Guang Phan, Leslie Mi Ok Chong, Steven Cha, Nicholas Ede, Bonnie Nixon, Anthony J Good

Institutions: Cabrini Hospital, Macquarie University, Chris O’Brien Lifehouse, Hackensack University Medical Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, The Ohio State University Wexner Medical Center, Mayo Clinic, Mayo Clinic Hospital, Garvan Institute of Medical Research

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286294247

Cites:

Cited by: 2

Related to: 10